Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals

Results show that for patients with uncontrolled blood pressure (BP) on renin angiotensin system (RAS) inhibitor monotherapy, switching to TWNYSTA® may: ¹

• deliver the blood pressure reductions needed to get them to BP goal
• demonstrate a rapid benefit, with over half of patients reaching office BP goal within 4 weeks and nearly 70% of patients within 12 weeks
• provide a safe and well-tolerated treatment option in this patient population

Ingelheim, Germany, 29 April 2012 - New data show that TWYNSTA®, a once daily, single pill combination of the angiotensin II receptor blocker (ARB) telmisartan and the calcium channel blocker (CCB) amlodipine, leads to rapid and sustained blood pressure (BP) reductions that can bring most patients with previously uncontrolled hypertension on RAS inhibitor monotherapy to BP goal effectively within 4 weeks. ¹